Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 05 SEPTEMBER 2024

The Future Looks Better For Cannabis Reform

Harris Sliwoski
Explore more from Harris Sliwoski

Earlier this year, the DEA initiated rulemaking to reclassify cannabis as a schedule III narcotic. This is probably the biggest news in cannabis reform since the Controlled Substances Act became law.

United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Author LinkedIn connections

Earlier this year, the DEA initiated rulemaking to reclassify cannabis as a schedule III narcotic. This is probably the biggest news in cannabis reform since the Controlled Substances Act became law.

A lot of folks had hoped that cannabis would be rescheduled in advance of the 2024 election. Those hopes were dashed when the DEA scheduled a hearing for the proposed reclassification about a month after the election. My colleague, Vince Sliwoski, wrote a post on DEA's hearing announcement here.

Since DEA announced the hearing in late August (and frankly even before then), I've seen a lot of speculation that if President Trump wins, he would derail the rescheduling. That didn't seem likely given that President Trump (while not very good on cannabis reform in his first term) hadn't really indicated an intent to derail the rescheduling process– if he even could.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

See more popular content from

Article

The Intoxicating Hemp Products Ban Was Delayed A Month. Now What?

The House has passed a short-term funding bill postponing the federal ban on hemp-derived THC products from November 12th to December 11th. With comprehensive legislation unlikely before the new deadline and competing interests from cannabis sellers, alcohol producers, and state regulators creating policy gridlock, the future of intoxicating hemp products remains uncertain as midterm elections approach.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski
Article

IRC Section 280E And Cannabis Tax Planning: Recent Developments And Practical Considerations

The landscape surrounding Section 280E of the Internal Revenue Code continues to evolve with President Trump's Executive Order on medical marijuana rescheduling, advancing litigation in New Mexico Top Organics v. Commissioner, and shifting regulatory signals. Cannabis taxpayers face critical decisions about taking "non-280E" positions on their tax returns while the IRS maintains its enforcement stance and the U.S. Tax Court case addressing common arguments remains pending.
United StatesCannabis & Hemp
Foley Hoag LLP
Foley Hoag LLP
Article

"Marijuana" Rescheduling Delayed, Again. What It Could Mean, And What Comes Next

The DEA's marijuana rescheduling hearing has been unexpectedly stayed following a motion to admit a new GAO report examining agency scheduling procedures. With the proceeding on hold and the medical marijuana Schedule III order facing legal challenges in the D.C. Circuit, the cannabis industry's path to federal tax relief through rescheduling has become increasingly uncertain.
United StatesCannabis & Hemp
Harris Sliwoski
Harris Sliwoski